Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of Female Genital Schistosomiasis

a female genital parasitic infection and treatment technology, applied in the field of tropical diseases, can solve the problems of increased mortality, less successful treatment of fgs, and increased risk of hiv infection, and achieve the effect of reducing the amount of adult worms

Pending Publication Date: 2021-08-26
VILLYA LLC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Reduces the number of worms and lesions, alleviates symptoms such as vaginal discharge, bleeding, and pelvic pain, and offers a prophylactic effect against HIV and human papillomavirus infections, with potential for complete or partial elimination of the infection.

Problems solved by technology

People with FGS are far more susceptible to HIV and human papillomavirus infections, which are associated with increased mortality.
FGS may also result in infertility.
While such treatment successfully treats systemic infection by worms, it is far less successful in treating FGS caused by adult schistosomiasis worms living on the other side of the tissue explicitly in the biome of the female reproductive system.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0029]Praziquantel powder (600 mg) was mixed with 2.5 g of K-YTM Jelly (Ingredients: Water, Glycerin, Hydroxyethylcellulose, Chlorhexidine, Gluconate, Gluconolactone, Methylparaben, Sodium Hydroxide.). A plastic vaginal applicator was loaded with the mixture for delivery to the subject. The mixture could include any vaginal lubrication as a medium, such as a jelly, gel, foam, or a liquid. Preferrably the medium is water soluble. The ingredients can be mixed by mechanical mixer or by hand to achieve a relatively homogeneous mixture.

example 2

[0030]Shistosomiasis is a blood-borne worm and generally resides in the circulatory system. We found that we are able to cure infected females with FGS of schistosomiasis in the blood but not the vaginal cavity.

[0031]A blood sample from a female with FGS was initially tested using Schisto POC-CCATM from ICT and confirmed to have a blood-borne infection of schistosomiasis. The female with FGS was then treated with three doses of 20 mg / kg oral praziquantel. After two weeks, blood of the female subject was retested and was found to be negative for schistosomiasis. However, observation of a vaginal sample from brushing with a swab was spread on microscope slides showed vaginal cells, fluid, blood, and live schistosomiasis worms still in the vagina.

[0032]A single dose of Praziquantel as described in Example 1 was vaginally inserted into the female subject. After two weeks, slides were observed under the microscope to be negative for schistosomiasis worms.

example 3

[0033]Praziquantel powder (1200 mg) is mixed with 20 ml normal saline (0.09% sodium chloride) and inserted using an intrauterine catheter. Mechanical or hand mixing of the ingredients is used to achieve a thorough combination of the ingredients, preferably dissolution.[0034]1. A unit dosage form of praziquantel, selected from the group consisting of:[0035]400-1000 mg praziquantel per 1.5-4.5 g vaginal vehicle;[0036]800-1500 mg praziquantel per 3-7 g vaginal vehicle;[0037]100-500 mg praziquantel per 1.5-4.5 g vaginal vehicle; or[0038]800-1500 mg praziquantel per 15-25 ml normal saline uterine vehicle.[0039]2. The unit dosage form of praziquantel of clause 1 wherein the vaginal vehicle is a cream, film, gel, or foam.[0040]3. A kit for locally treating female genital tissue infected with schistosomes, comprising:[0041]a vaginal applicator; and[0042]praziquantel.[0043]4. The kit of clause 3 further comprising a water soluble vehicle.[0044]5. The kit of clause 4 wherein the vaginal vechi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

Formulations of praziquantel are used to locally treat female genital schistosomiasis. The formulations can be applied to the upper or lower female genital tract, depending on the location of the infection. Thick or viscous formulations can be used advantageously in the vagina. Solutions of active ingredient can be instilled in the uterus.

Description

TECHNICAL FIELD OF THE INVENTION[0001]This invention is related to the area of tropical diseases. In particular, it relates to female genital parasitic infection.BACKGROUND OF THE INVENTION[0002]Schistosomiasis (also known as bilharziasis) is a worm infection endemic to tropical areas. Human schistosomiasis is widespread in both rural and urban areas of the world. The worms infect people via skin contact with infested fresh water. The worms lay eggs in the host human, some of which reside in organs, such as the cervix, uterus, fallopian tubes, or lower female genital tract, and some of which are excreted. The eggs, which stimulate a the host inflammatory response and increased vascularization, produce lesions.[0003]Female genital schistosomiasis (FGS) is caused by schistosome eggs deposited in genital tissues. According to the World Health Organization, FGS may be the most common gynecological condition in schistosomiasis-endemic areas. People with FGS are far more susceptible to HI...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5025A61K9/06A61K9/00A61P33/12A61K9/02
CPCA61K31/5025A61K9/06A61K9/02A61P33/12A61K9/0053A61K9/0034A61K9/08A61K47/02A61K47/12A61K47/38A61K47/10A61K47/16A61K47/14A61K47/08Y02A50/30A61K31/4985A61K31/7048A61K2300/00
Inventor MILLER, WILLIAM
Owner VILLYA LLC